< Back to all News

Perceiv AI: Predicting Disease Progression to Transform Interventions

Impact

Seeing into the future is a superpower many used to only dream of, but never experience. Now, that dream is becoming a reality.

Perceiv AI, a Canadian medical technology company based out of Montreal, Quebec, has created an AI-powered platform that accurately predicts the progression of age-related diseases, such as Alzheimer’s disease.

Through comprehensive analysis of personalized data (e.g., clinical variables, biomarkers, genetics, imaging, etc.), Perceiv AI’s innovative platform – Foresight – offers insights into the future of a patient’s disease.

Thanks to the support of the CABHI MC2 [now Fuel] program, we have successfully deployed our enterprise-grade Foresight platform, which is fully secure and compliant.

Christian Dansereau, CEO of Perceiv AI

The use of Perceiv AI’s Foresight platform has the power to transform and accelerate clinical trials by identifying candidates who, based on their health data, would yield the best outcomes, and companies are taking notice. In January 2024, Perceiv AI partnered with Alleo Labs, a US-based biotechnology company that plans to use Foresight to select candidates for its clinical trials.

As Perceiv AI continues to enable prospective drug clinical trials and support physicians with timely diagnoses, its impact will continue to spread.

Subscribe to the CABHI newsletter

* indicates required